Every material Form 8-K KYNTRA BIO, INC. has filed with the SEC since August 31, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Nasdaq's Listing Qualifications Staff determined to delist Kyntra Bio's common stock after the company did not show compliance with Listing Rule 5450(b) by the September 29, 2026 deadline. Kyntra Bio has requested a hearing before a Nasdaq Hearings Panel, and the stock will keep trading under KYNB while the Panel decides, so shareholders face continued uncertainty over the listing.
Staff determination letter dated September 30, 2026; compliance deadline was September 29, 2026
Company timely requested a Nasdaq Hearings Panel review, which stays the suspension and delisting
Extension period could be up to 180 days from the Staff determination under Listing Rule 5815(c)(1)(A)
Company previously received a April 2, 2026 notice on total assets, total revenue and stockholders' equity or market value standards; no assurance the Panel will grant continued listing
Kyntra Bio appointed Andrew E. Singer, MBA, as a Class III director effective October 1, 2026, and named him to the Audit Committee. Director Maykin Ho, Ph.D., resigned from the board effective September 30, 2026, and the filing says her resignation was not the result of any disagreement with the company. The company also entered a new three-year change in control and severance agreement with CEO Thane Wettig, which the filing says has no material changes to compensation or benefits.
Andrew E. Singer, MBA, appointed Class III director effective October 1, 2026, with a term expiring in 2029 and a seat on the Audit Committee
Maykin Ho, Ph.D., resigned from the board effective September 30, 2026; she joined the board in December 2018
New change in control and severance agreement with CEO Thane Wettig dated September 30, 2026, with a term ending October 2, 2029, replacing the prior agreement
Filing states there were no material changes to compensation or benefits under the CEO agreement
Kyntra Bio amended its royalty financing agreement with NQ Project Phoebus, L.P., lowering the maximum aggregate payments from $125 million to $65 million in exchange for a $42.6 million accelerated upfront payment. The company says the amendment and the FibroGen Europe bankruptcy together reduce its future liabilities by approximately $80 million, but pro forma cash, cash equivalents, investments, and accounts receivable fall to $53.1 million from $95.7 million as of June 30, 2026.
Maximum aggregate payments reduced from $125 million to $65 million, a $60 million reduction in payment obligations
$42.6 million upfront payment brings total payments to NQ Project Phoebus to $50 million, a full return of its invested capital
Remaining $15 million cap to be paid from 50% of Astellas revenue for EVRENZO sales in Europe and other Astellas territories excluding Japan
Pro forma cash and related balances of $53.1 million as of June 30, 2026; company expects cash runway into the fourth quarter of 2027
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every KYNTRA BIO, INC. filing is on SEC EDGAR ↗. 8-K briefs of other companies →